cber organizational chart - MARKETS
CBER is the Center within FDA that regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. The Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration's (FDA) regulates a variety of products, and verifies or enforces requirements at the time the products are imported or offered for import into the US. CBER regulates a number of biologics-related products, including blood tests, computer software, and devices related to blood transfusion, which industry representatives would like to see handled by the much brisker Center for Devices and Radiological Health.
Understanding the Context
The purpose of CBER is to conduct rigorous research and translate and disseminate empirically-supported practices that promote equity and improve educational outcomes for all learners, especially those with or at risk for learning and behavioral difficulties. Home | Center for Behavioral Education and Research (CBER) | Neag ... When a biological product receives CBER approval, it signals that the product has undergone scientific scrutiny and meets regulatory benchmarks. This assurance allows patients and healthcare providers to have confidence in the therapies they use.
Image Gallery
Key Insights
Prasad was first appointed head of the FDA's Center for Biologics Evaluation and Research (CBER) in May 2025 – after his predecessor Peter Marks resigned, reportedly before being pushed out by ... The Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) released the 2026 guidance agenda on Friday, outlining topics the agency is considering for guidance development this year.